A multifunctional catalyst that stereoselectively assembles prodrugs

The catalytic stereoselective synthesis of compounds with chiral phosphorus centers remains an unsolved problem. State-of-the-art methods rely on resolution or stoichiometric chiral auxiliaries. Phosphoramidate prodrugs are a critical component of pronucleotide (ProTide) therapies used in the treatm...

Full description

Saved in:
Bibliographic Details
Published inScience (American Association for the Advancement of Science) Vol. 356; no. 6336; pp. 426 - 430
Main Authors DiRocco, Daniel A., Ji, Yining, Sherer, Edward C., Klapars, Artis, Reibarkh, Mikhail, Dropinski, James, Mathew, Rose, Maligres, Peter, Hyde, Alan M., Limanto, John, Brunskill, Andrew, Ruck, Rebecca T., Campeau, Louis-Charles, Davies, Ian W.
Format Journal Article
LanguageEnglish
Published United States American Association for the Advancement of Science 28.04.2017
The American Association for the Advancement of Science
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The catalytic stereoselective synthesis of compounds with chiral phosphorus centers remains an unsolved problem. State-of-the-art methods rely on resolution or stoichiometric chiral auxiliaries. Phosphoramidate prodrugs are a critical component of pronucleotide (ProTide) therapies used in the treatment of viral disease and cancer. Here we describe the development of a catalytic stereoselective method for the installation of phosphorus-stereogenic phosphoramidates to nucleosides through a dynamic stereoselective process. Detailed mechanistic studies and computational modeling led to the rational design of a multifunctional catalyst that enables stereoselectivity as high as 99:1.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0036-8075
1095-9203
DOI:10.1126/science.aam7936